You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

Diabetes Care Strategies: Achieving Tight Glucose and Metabolic Targets Early and Safely

  • Authors: Melanie Davies, MD; Juan Pablo Frias, MD; Filip K. Knop, MD, PhD
  • CME Released: 11/30/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 11/30/2023, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US diabetologists and endocrinologists as well as primary care physicians.

The goal of this activity is for learners to better understand the importance of metabolic health in diabetes care and the feasibility of achieving better metabolic health by using novel incretin-based therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Need to attain early tight glycemic control in patients with type 2 diabetes (T2D)
    • Central role of weight control for better metabolic and health outcomes in the management of T2D
  • Have greater competence related to
    • Development of personalized treatment targets and plans in conjunction with the patient


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Melanie Davies, MD

    Professor of Diabetes Medicine,
    University of Leicester and University Hospitals of Leicester NHS Trust
    Leicester Diabetes Centre
    Leicester, United Kingdom

     

    Disclosures

    Melanie Davies, MD, has the following relevant financial relationships:
    Consultant or advisor for: Boehringer Ingelheim; Lexicon; Lilly; Novo Nordisk; Pfizer; Sanofi; ShouTi Pharma Inc
    Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Lilly; Napp Pharmaceuticals; Novartis; Novo Nordisk; Sanofi
    Research funding from: AstraZeneca; Boehringer Ingelheim; Janssen; Novo Nordisk; Sanofi-Aventis

  • Juan Pablo Frias, MD

    Medical Director and Principal Investigator,
    Velocity Clinical Research
    Los Angeles, California, United States
    Assistant Clinical Professor of Medicine
    Division of Endocrinology
    University of California, San Diego
    San Diego, California, United States

     

    Disclosures

    Juan Pablo Frias, MD, has the following relevant financial relationships:
    Consultant or advisor for: 89bio; Akero; Altimmune; Axcella Health; Becton Dickenson; Boehringer Ingelheim; Carmot Therapeutics; Echosens; Eli Lilly; Gilead; Intercept; Merck; Metacrine; Novo Nordisk; Pfizer; Sanofi
    Speaker or member of speakers bureau for: Eli Lilly; Merck; Sanofi
    Research funding from: 89bio; Akero; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly; Intercept; IONIS; Janssen; Madrigal; Merck; Metacrine; NorthSea Therapeutics; Novartis; Novo Nordisk; Oramed; Pfizer; Poxel; Sanofi 

  • Filip K. Knop, MD, PhD

    Professor of Clinical Endocrinology and Consultant Endocrinologist
    Gentofte Hospital
    University of Copenhagen
    Hellerup, Denmark

     

    Disclosures

    Filip K. Knop, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Boehringer Ingelheim; Dawn Health; Eli Lilly; Merck Sharp & Dohme/Merck; Novo Nordisk; Sanofi; ShouTi; Zealand Pharma; Zucara
    Speaker or member of speakers bureau for: AstraZeneca; Bayer; Boehringer Ingelheim; Eli Lilly; Merck Sharp & Dohme/Merck; Novo Nordisk; Sanofi; Zealand Pharma
    Research funding from: AstraZeneca; Boehringer Ingelheim; Gubra; Novo Nordisk; Sanofi; Zealand Pharma
    Contracted researcher for: Allergan; Novo Nordisk; Sanofi
    Patent beneficiary of: Antag Therapeutics developing a glucose-dependent insulinotropic receptor antagonist for the treatment of metabolic diseases

Editors

  • Lorena Casadonte

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Lorena Casadonte has no relevant financial relationships.

  • Grace O’Malley, PhD

    Associate Medical Education Director, WebMD Global, LLC

    Disclosures

    Grace O’Malley, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and Leicester Diabetes Centre.

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Diabetes Care Strategies: Achieving Tight Glucose and Metabolic Targets Early and Safely

Authors: Melanie Davies, MD; Juan Pablo Frias, MD; Filip K. Knop, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 11/30/2022

Valid for credit through: 11/30/2023, 11:59 PM EST

processing....

  • Print